ReNewVax has been named ‘One to Watch’ in UKTN’s 2023 guide to University Spinouts.
University spinouts are companies founded to commercialise innovative technologies, products or services that have originated from academic research conducted within universities. Bridging the gap between academia and entrepreneurship, spinouts translate discoveries into viable business ventures. As a unique form of startup, they come with their own benefits and risks.
Featuring a range of companies across different sectors, the guide details the spinout lifecycle, what makes a successful spinout, investment considerations, and interesting case studies.
ReNewVax’s Chief Scientific Officer, Dr. Marie O’Brien, said, “It’s a real honour to be featured in this guide alongside so many other innovative companies in different industries.
Since spinning out of the University of Liverpool in 2019, we have developed a strong team of employees and collaborators to help us reach our goal of getting our pneumococcal vaccine to clinical trials in 2025, so it’s great to be recognised for the steps we have taken to build on the academic research that had led us to this point.”
The guide explores the key factors and metrics that contribute to a successful spinout, such as research, building a strong team, utilising market validation, and appropriate metrics for success.
To read the piece, visit https://www.uktech.news/guide/a-guide-to-university-spinouts